作者
Giuseppe Mancia, Guy De Backer, Anna Dominiczak, Renata Cifkova, Robert Fagard, Giuseppe Germano, Guido Grassi, Anthony M Heagerty, Sverre E Kjeldsen, Stephane Laurent, Krzysztof Narkiewicz, Luis Ruilope, Andrzej Rynkiewicz, Roland E Schmieder, Harry AJ Struijker Boudier, Alberto Zanchetti, Alec Vahanian, John Camm, Raffaele De Caterina, Veronica Dean, Kenneth Dickstein, Gerasimos Filippatos, Christian Funck-Brentano, Irene Hellemans, Steen Dalby Kristensen, Keith McGregor, Udo Sechtem, Sigmund Silber, Michal Tendera, Petr Widimsky, Jose Luis Zamorano, Sverre E Kjeldsen, Serap Erdine, Krzysztof Narkiewicz, Wolfgang Kiowski, Enrico Agabiti-Rosei, Ettore Ambrosioni, Renata Cifkova, Anna Dominiczak, Robert Fagard, Anthony M Heagerty, Stephane Laurent, Lars H Lindholm, Giuseppe Mancia, Athanasios Manolis, Peter M Nilsson, Josep Redon, Roland E Schmieder, Harry AJ Struijker-Boudier, Margus Viigimaa, Gerasimos Filippatos, Stamatis Adamopoulos, Enrico Agabiti-Rosei, Ettore Ambrosioni, Vicente Bertomeu, Denis Clement, Serap Erdine, Csaba Farsang, Dan Gaita, Wolfgang Kiowski, Gregory Lip, Jean-Michel Mallion, Athanasios J Manolis, Peter M Nilsson, Eoin O'Brien, Piotr Ponikowski, Josep Redon, Frank Ruschitzka, Juan Tamargo, Pieter van Zwieten, Margus Viigimaa, Bernard Waeber, Bryan Williams, Jose Luis Zamorano
发表日期
2007/6/1
来源
European heart journal
卷号
28
期号
12
页码范围
1462-1536
出版商
Oxford University Press
简介
Recommendations about therapy for hypertension are here preceded by some considerations on the strength of available evidence on the benefits associated with antihypertensive treatment as well as on the comparative benefits of the various classes of drugs. There is a consensus that large randomized trials measuring fatal and non-fatal events represent the strongest type of evidence available. However, it is commonly recognized that event based randomized therapeutic trials also have limitations. 3,273,274 These include the need to select elderly or otherwise high risk patients in order to maximize the number of events collected and thus the power of trials, which means that uncomplicated, younger and lower risk patients are rarely represented, with the unfortunate consequence that little direct information is available on treatment benefits in a large sector of the hypertensive population. Furthermore, the …
引用总数
学术搜索中的文章
G Mancia, G De Backer, A Dominiczak, R Cifkova… - European heart journal, 2007
G Mansia, G De Backer, A Dominiczak, R Cifkova… - Blood pressure, 2007
G Mancia, G De Backer, A Dominiczak, R Fagard… - Blood pressure, 2007
GIW Germano, G De Backer, A Dominiczak, R Cifkova… - European Heart Journal, 2007